Predictors Found for Durable Response to BCMA CAR T Therapy in Multiple Myeloma

Researchers at the Icahn School of Medicine at Mount Sinai have identified specific features of the immune system help explain why some patients with multiple myeloma (MM) experience long-term remission following CAR T cell therapy, while others relapse within a few years. The research, published in Blood Advances , focused on the BCMA-targeted therapy cilta-cel and found that long-term MM survival was linked to an interaction between the infused CAR T cells and a patient’s own immune system.

“CAR T cell therapy has changed myeloma care, but not everyone maintains a long remission,” said senior author Alessandro Lagana, PhD, assistant professor of oncological sciences at the Icahn School of Medicine at Mount Sinai. “We wanted to understand what’s happening in the immune system of pa